---
title: "Regulatory roadmap: FDA Class III medical device, United States"
url: https://normiq.app/en/roadmap/united-states/fda-class-iii
language: en
updated: 2026-11-17
---

# Regulatory roadmap: FDA Class III medical device, United States

6 phases · 37 steps

This is the order in which Normiq organises market access for the market "United States" and the category "FDA Class III medical device". Each step has a detailed guide — how to proceed, best practices, common mistakes, reference articles — reserved for Normiq accounts.

1. Phase 1

   ## Classification and regulatory strategy (FDA)

   Determine which regulation number and class the device falls under, whether a premarket submission is due, and through which route to request it.

   1. ### Establish the class and the generic type

      required · 10 d

      The class follows from the generic type the device belongs to, and from the controls FDA deemed necessary for that type.

   2. ### Identify the product code

      required · 5 d

      The code by which FDA designates the generic category of the device. It governs registration, listing and the search for a predicate.

   3. ### Check exemptions, and their limits

      required · 10 d

      Some devices escape premarket submission, others good manufacturing practices. No exemption is unconditional.

   4. ### Request FDA feedback before submitting (Q-Submission)

      recommended · 90 d

      A voluntary channel to validate a testing strategy or an acceptability question before filing. Nothing compels it, and nothing binds FDA.

   5. ### Qualify a software function

      recommended · 10 d

      Five families of software functions are excluded from the device definition. The exclusion attaches to the function, not to the product.

2. Phase 2

   ## Establishment, listing and US agent (FDA)

   Register with FDA, list the devices, and appoint the US agent without whom a foreign manufacturer does not exist for the agency.

   1. ### Appoint a US agent

      required · 20 d

      Every foreign establishment appoints one, and only one. Informing the agent is equivalent to informing the manufacturer.

   2. ### Register the establishment

      required · 30 d

      Initial registration within thirty days of starting operations, then annual renewal between 1 October and 31 December.

   3. ### List the devices

      required · 10 d

      Listing declares which devices are placed in distribution, under which submission number and from which establishment.

   4. ### Identify the initial importer

      recommended · 5 d

      Three capacities the regulation separates and practice confuses: initial importer, importer, and person who imports.

   5. ### Apply for small business status

      recommended · 60 d

      A fee reduction, subject to turnover thresholds, to be requested each fiscal year. One of the two windows closes before the other.

3. Phase 3

   ## Quality management system — QMSR (FDA)

   Since 2 February 2026, 21 CFR 820 incorporates ISO 13485:2016 by reference and adds its own requirements. An ISO certificate is not enough.

   1. ### Measure the gap between ISO 13485 and the QMSR

      required · 90 d

      What 21 CFR 820 adds to the standard: four cross-references, mandated records, and control of labelling.

   2. ### Apply design controls

      required · 60 d

      Classes II and III, plus any software-driven device and five named product codes — including in class I.

   3. ### Handle complaints and link them to vigilance

      required · 30 d

      Seven mandatory fields per complaint, and two mandated bridges to adverse event reporting and advisory notices.

   4. ### Prepare for an FDA inspection

      required · 30 d

      Since February 2026 the inspection method has changed, and documents once shielded no longer are.

   5. ### Secure electronic records

      recommended · 45 d

      Part 11 applies as soon as a record required by regulation exists in electronic form.

4. Phase 4

   ## Premarket submission (FDA)

   The 510(k), the De Novo, the PMA: which route, which evidence, which timelines, and what each decision actually authorises.

   1. ### Choose the predicate and show substantial equivalence

      recommended · 30 d

      One predicate carries the demonstration. The 2014 guidance sets out six successive decisions, and forbids mixing two devices.

   2. ### Assemble the performance data

      required · 120 d

      A staircase: description, bench testing, animal and biocompatibility studies, then clinical data — which fewer than one dossier in ten carries.

   3. ### Document a software function

      recommended · 45 d

      Two documentation levels, Basic and Enhanced, and ten elements of which only three change from one level to the other.

   4. ### Meet the cybersecurity obligations (524B)

      recommended · 60 d

      Three statutory obligations for a « cyber device ». The definition is broader than it looks: a USB port is enough.

   5. ### File the 510(k) through eSTAR

      recommended · 30 d

      Since 1 October 2023 a 510(k) is filed in eSTAR format through the CDRH Portal. The content remains that of 807.87.

   6. ### Follow the review and wait for the order

      recommended · 90 d

      Two ninety-day deadlines coexist and do not mean the same thing. No marketing before the equivalence order.

   7. ### Decide whether a change requires a new submission

      required · 15 d

      Two criteria, and a threshold that turns on the potential of the change, not on its demonstrated effect.

   8. ### Request a De Novo classification

      recommended · 120 d

      The route for a device with no predicate. Fifteen days for acceptance, one hundred and twenty for the decision, and the result becomes a predicate.

   9. ### File a premarket approval application (PMA)

      required · 180 d

      The class III route. Forty-five days to filing, one hundred and eighty to the decision. Structure laid down, to be deepened.

   10. ### Run a clinical investigation (IDE)

       required · 60 d

       FDA silence at thirty days is enough to begin. But the significant-risk question must have been settled first. Structure laid down.

   11. ### Apply for a humanitarian device exemption (HDE)

       recommended · 75 d

       A route reserved for conditions affecting no more than eight thousand people, which waives proof of effectiveness — not of safety. Structure laid down.

   12. ### Have a test categorised under CLIA

       recommended · 60 d

       A regime distinct from FDA authorisation, which decides in which laboratories a test may be run.

5. Phase 5

   ## Labelling, instructions and unique device identifier (FDA)

   What the label must carry, what the instructions must say, and the unique identifier to be submitted to the GUDID database.

   1. ### Compose the labelling

      required · 30 d

      Name and place, directions a layman can follow, symbols under conditions, and a date format that is imposed.

   2. ### Label an in vitro diagnostic

      recommended · 20 d

      Nine items on the label, fifteen headings in the insert — and in the order the regulation fixes.

   3. ### Apply the unique identifier and populate the GUDID

      required · 45 d

      Two forms on the label, direct marking for reusables, and a submission to the database no later than the labelling date.

   4. ### Control promotion and advertising

      recommended · 15 d

      Advertising is not neutral: it contributes to establishing the intended use of the device, and hence its regime.

6. Phase 6

   ## Vigilance and post-market obligations (FDA)

   Report adverse events, notify corrections and removals, run a recall, and keep the annual registration current.

   1. ### Report adverse events (Medical Device Reporting)

      required · 30 d

      Thirty calendar days for a death, serious injury or malfunction; five working days where remedial action is called for.

   2. ### Report corrections and removals

      required · 10 d

      Ten working days to report a correction or removal intended to reduce a risk. An improvement without a violation is exempt.

   3. ### Run a recall, or recognise an enhancement

      required · 30 d

      A recall is voluntary; it is FDA that classifies it. The decisive criterion is not risk but the existence of a violation.

   4. ### Answer a surveillance order (section 522)

      recommended · 30 d

      An obligation born of an FDA order, never of itself. Thirty days to propose a plan.

   5. ### Set up ordered device tracking

      recommended · 30 d

      Like surveillance, device tracking arises from an FDA order. The patient may refuse to appear in it.

   6. ### Renew the registration and the listing

      required · 10 d

      Every year, from 1 October to 31 December, and confirmation is due even where nothing has changed.

The detailed guide for each step — how to proceed, best practices, common mistakes — is reserved for Normiq accounts.

## Track these deadlines device by device

Normiq places every deadline in your device's roadmap, with the steps that lead to it. Free 7-day trial.

[Open this roadmap in Normiq](https://normiq.app/signup)

## Other pathways on this market

- [FDA Class I medical device](https://normiq.app/en/roadmap/united-states/fda-class-i)
- [FDA Class II medical device](https://normiq.app/en/roadmap/united-states/fda-class-ii)
